Because we have previously shown the prognostic value of metabolic response to endocrine treatment on Progression Free Survival in metastatic BC patients [20], we decided to prospectively assess the value of metabolic response to NET in a homogenous population of postmenopausal women with non-metastatic, ER+/HER2- BC included in a clinical trial. This evidence concerns the gene ESR1 and breast cancer.